with the accumulation of HIV-1 drug-resistance mutations (DRMs) [3] [4] [5] , which may limit subsequent drug options and constitutes a source for onward transmission. Studies from the region have reported high levels of drug resistance in individuals with prolonged first-line ART failure, including complex nucleoside reverse transcriptase inhibitor (NRTI) resistance profiles, such as K65R, Q151M, and thymidine analogue mutations (TAMs), in addition to highly prevalent M184V and nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations [4] [5] [6] [7] [8] . Most reports on HIV-1 drug resistance deal with subtype B infections in developed countries. There is limited knowledge of resistance pathways in the different HIV-1 non-B subtypes and their clinical relevance [9] , despite the fact that .90% of HIV-1 infections globally belong to non-B subtype variants [10] .
The PASER-Monitoring (PASER-M) study is a prospective cohort of HIV-1-infected individuals from 13 [11] . The present study assessed HIV-1 DRMs in participants with virological failure of different first-line regimens and predicted viral drug susceptibility to gain insight about the optimal strategies for second-line therapy.
METHODS

Study Population
The PASER-M study includes clinical sites in Kenya (2), Nigeria (1), South Africa (3), Uganda (3), Zambia (3), and Zimbabwe (1) [11] . We previously reported the participants' baseline resistance profiles [12] and the effect of pretreatment drug resistance on the immunological and virological patient outcomes after the first year of ART [13] .
For the present analysis, individuals were included if they were aged $18 years with HIV-1 infection and had initiated standard first-line NNRTI-based ART in accordance with national guidelines-that is, advanced immunodeficiency (CD4 cell count ,200 cells/lL) or advanced HIV disease (WHO clinical stage 3 or 4) [13] . Individuals who were previously exposed to any antiretroviral drugs for prevention and/or treatment were excluded. Other exclusion criteria were pregnancy at study screening or, for those screened in Nigeria only, HIV type 2 coinfection.
Participants provided written informed consent at enrollment. The study protocol was approved by the appropriate national and local research ethics committees at all collaborating sites and the Academic Medical Center of the University of Amsterdam in the Netherlands.
Data Collection
Participants were followed up in accordance with local standardof-care guidelines. A single-drug substitution, due to toxicity or intolerance, was not considered a regimen switch. Plasma was collected at the baseline visit and after 12 months of ART (time window, 11-15 months) and was stored for retrospective assessment of HIV RNA and genotypic drug resistance. Virologic failure was defined as a plasma HIV RNA value of $400 copies/mL. Participants who were switched to second-line ART earlier than month 12 (owing to locally diagnosed ART failure) were not included in the month 12 summary statistics.
Virological Analysis
All virological testing was conducted at 1 of 2 reference laboratories in South Africa or Uganda, as previously described [12] . In brief, HIV RNA was determined using the NucliSens EasyQ real-time assay, version 2.0 (bioMérieux, Lyon, France) or COBAS Ampliprep/COBAS TaqMan assay (Roche, Branchburg, New Jersey). Population-based genotyping of HIV-1 protease and reverse transcriptase was undertaken in specimens with HIV RNA of .1000 copies/mL, using in-house sequencing methods. HIV-1 subtypes were inferred from the pol sequences using the STAR algorithm [14] and, if required, the REGA tool, version 2.0 [15] . Genotypic drug resistance was defined as the presence of $1 major amino acid substitution included in the International Antiviral Society-USA mutation list of December 2010 [16] . Drug classes considered were NRTIs, NNRTIs, and protease inhibitors (PIs). HIV-1 drug susceptibility for each participant was predicted using the Stanford algorithm, version 6.1.0 [17] and was categorized as susceptible, potential low-level resistance, low-level resistance, intermediate resistance, or high-level resistance. All sequences have been deposited in GenBank (accession numbers JQ480157-JQ480298).
Statistical Analysis
Group comparisons for categorical data were done using v 2 or
Fisher exact test, and for continuous data using the KruskalWallis test, as appropriate. The Mantel-Haenszel method was used to compute weighted odds ratios (ORs) that adjusted for a single confounding factor. Reported P values are 2-sided, and P , .05 was considered statistically significant. All analyses were performed using Stata version 11 (StataCorp, College Station, Texas).
RESULTS
Study Population and Clinical Outcomes
Between March 2007 and September 2009, 2588 participants were enrolled. (Figure 2 ). In 2 (1.4%) participants, DRMs known to be associated with PIs were observed (both tipranavir-associated Q58E); no triple-class resistance was detected. Exclusion of the 16 (9.6%) participants who had $1 single-drug substitution during the first year of ART did not significantly change the frequencies of the DRMs (not shown).
Of the NRTI-associated DRMs (Figure 3 ), M184V was the most frequent (76 [53.5%]), followed by K65R (17 [12. 0%]) and any TAM (12 [8.5%] ). In 9 (6.3%) participants, $2 TAMs were detected, and in 3 (2.1%) participants, $3 TAMs were detected. TAM-1 mutations included M41L and T215 F/Y (L210W not observed); TAM-2 mutations included D67N, K219E, and K70R (K219Q not observed). In participants who failed regimens containing zidovudine, stavudine, or tenofovir, $1 Compared with participants with virological failure by month 12 who did not harbor any DRM, those with $1 DRM had a marginally lower median HIV RNA (4.33 vs 4.71 log 10 copies/mL; P 5 .04); this difference was least pronounced for NNRTI resistance (4.30 vs 4.55 log 10 copies/mL; P 5 .05) and most pronounced for M184V (4.21 vs 4.59 log 10 copies/mL, P 5 .02).
Of the 142 participants with a genotype result by month 12, 135 had a baseline genotype result (7 baseline specimens not collected); of these, 14 (10.4%) participants harbored $1 DRM before start of ART. Of the DRMs detected by month 12, 96% were newly acquired during the first year of ART.
HIV-1 Subtype Diversity
Among the 142 participants who had a resistance test result by month 12, HIV-1 subtype C was most commonly identified, followed by A, D, A/G recombinant, and other subtypes/ recombinants ( Table 1 ). The subtype distribution did not differ significantly between those with or without DRMs (P 5 .14). The DRMs according to subtype are shown in Figure 4 . K65R was more frequent in subtype C (12 [ (Figure 4 ).
Predicted Genotypic Drug Susceptibility
Of the viruses harboring $1 DRM (n 5 100), the predicted HIV-1 susceptibility to lamivudine and emtricitabine was reduced in the majority (81%) due to the high frequency of M184V ( Figure 5 ). For the other NRTIs, reduced HIV-1 susceptibility was predicted for abacavir in 42% of sequences, didanosine in 40%, tenofovir in 27%, stavudine in 18%, and zidovudine in 10%. For Figure includes the viruses that harbored $1 drug-resistance mutation (n 5 100). Genotypic drug susceptibility was predicted using the Stanford HIVdb algorithm (version 6.1.0). Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; NVP, nevirapine; RPV, rilpivirine; TDF, tenofovir.
the NNRTIs, reduced HIV-1 susceptibility was frequently predicted for the first-generation drugs efavirenz and nevirapine (93%) and less frequently for the second-generation drugs etravirine and rilpivirine (59%). High-level resistance was most frequently predicted for nevirapine (92%), followed by lamivudine/ emtricitabine (77%) and efavirenz (73%), but was uncommon for etravirine and rilpivirine (5%). Reduced HIV-1 susceptibility was not predicted for any of the ritonavir-boosted PIs.
DISCUSSION
This multicountry cohort study examined HIV-1 resistance mutation patterns in African patients with virological failure on different first-line ART regimens and predicted their impact on second-line drug susceptibility. After the first year of ART, 70% of those with virological failure had a virus with $1 DRM, and dual-class resistance was observed in 49%. Nearly all (96%) DRMs detected by month 12 were newly acquired in the first year of ART. Previous studies from the region have reported higher frequencies (83%-93% of those with virological failure) and complexity of DRM patterns in persons with prolonged ART failure in the absence of viral load monitoring [4] [5] [6] [7] [8] . By contrast, in the present study, routine viral load testing after 12 months of ART enabled the relatively early detection of virological ART failure, which, to some extent, may have prevented the accumulation of resistance. Nonetheless, observed resistance patterns were more extensive for this cohort than for cohorts that received intensive virological monitoring in South Africa [18] and resource-rich countries [19, 20] . Therefore, our data underscore the importance of implementing routine viral load monitoring in ART programs in sub-Saharan Africa to prevent drug-resistance accumulation [3] [4] [5] . The presence of DRMs was associated with lower HIV RNA values, which result from the reduced fitness of resistant variants.
In patients who failed a tenofovir-containing regimen, the K65R mutation, which is tenofovir's signature mutation, was commonly observed. Notably, K65R, rather than TAMs, was also frequently selected after stavudine failure. This finding concurs with previous clinical studies that reported high rates of K65R in subtype C-infected Africans who failed stavudinecontaining regimens [4, 5, 7] and contrasts with the low frequencies of K65R observed in subtype B-infected individuals from developed countries [21, 22] . K65R and TAMs represent antagonistic pathways of NRTI resistance [23] , and K65R confers cross-resistance to all NRTIs except zidovudine.
Several mechanistic studies have demonstrated in vitro that the K65R mutation, which confers broad cross-resistance to the NRTI class, develops more readily in HIV-1 subtype C, the predominant subtype in sub-Saharan Africa, than in subtype B [24] [25] [26] [27] [28] [29] . In our cohort, which included only non-B subtypes, K65R was detected more frequently in subtype C than in subtypes A or D. However, after adjusting for differential stavudine and tenofovir use across the subtypes, the association was not statistically significant. This discrepancy with the published literature is most likely explained by the limited statistical power of the present study to assess the effects of subtype on the rates of individual DRMs. Nonetheless, overall, our data support the conclusion that K65R is frequently selected after stavudine or tenofovir use in African populations receiving first-line ART. Therefore, from a virological perspective, zidovudine rather than tenofovir (as currently recommended by the WHO guidelines [30] ), may be preferred in second-line therapy for non-B subtype-infected patients who fail a stavudine-containing first-line regimen in the absence of stringent viral load and resistance monitoring. This scenario would warrant enhanced toxicity monitoring, particularly for zidovudine-associated anemia [31] .
WHO advises that stavudine be phased out of first-line regimens due to its serious adverse effects, to be replaced with either tenofovir or zidovudine [30] . Dose reduction (from 40 mg to 30 mg, and even 15-20 mg per day) has been suggested to limit the mitochondrial toxicities from stavudine [32] . However, suboptimal dosing of stavudine might, in theory, result in even more frequent emergence of K65R, particularly when used as part of NNRTI-based regimens. Emerging K65R will compromise future NRTI backbones, and clinical trials are ongoing to establish the effectiveness of (''simplified'') PI-based second-line therapy without an effective NRTI backbone [33] .
For second-line ART, WHO recommends a ritonavir-boosted PI (preferably lopinavir or atazanavir), with a dual backbone of 2 new or recycled NRTIs, that is, tenofovir plus lamivudine/emtricitabine (after use of stavudine or zidovudine in first-line) or zidovudine plus lamivudine (after use of tenofovir in first-line) [30] . In our cohort, HIV-1 susceptibility to all PIs was preserved for all participants; zidovudine and tenofovir susceptibility was preserved in the majority of patients who failed first-line ART (90% and 73%, respectively). This means that the majority of patients who are switched empirically to second-line, PI-based therapy will receive at least 2 active drugs. Preliminary studies in Africa have indeed suggested high chance of viral resuppression with empirically prescribed second-line regimens [34] [35] [36] [37] [38] .
The second-generation NNRTIs rilpivirine or etravirine are being considered as second-line drugs in resource-limited countries in patients previously exposed to efavirenz or nevirapine because of their different resistance profiles and suggested high genetic barrier. Susceptibility to the second-generation NNRTIs is preserved in viruses containing the K103N mutation, preferentially selected by efavirenz, but susceptibility is reduced in the presence of Y181C, preferentially selected by nevirapine [39] . In our cohort, viral susceptibility to the second-generation NNRTIs was already reduced in 59% of participants who had $1 DRM. Given that NRTI and NNRTI resistance mutations rapidly accumulate in the absence of viral load monitoring [4, 5] , second-line regimens based on 2 NRTIs and a secondgeneration NNRTI are unlikely to be effective. Instead, use of second-generation NNRTIs as part of first-line ART in resourcelimited countries merits further evaluation.
In our cohort, K103N occurred more frequently in subtype D infections than in subtype C infections. By contrast, previous studies in women and infants after the use of single-dose nevirapine to prevent vertical HIV-1 transmission have suggested that K103N accumulates faster in subtype C than D and faster in D than A [40] [41] [42] . Additional studies are needed to elucidate the virological mechanisms for different subtypes.
This study has some limitations. Population-based sequencing is not able to detect minority resistant viral strains, thus potentially underestimating resistance [43] . The lack of frequent serial blood sampling after ART initiation precluded a more detailed analysis of the evolution of DRMs after ART initiation.
The number of HIV-1-infected persons accessing ART in resource-limited countries is projected to increase further in view of the goal of universal access [2] and, particularly, the earlier start of ART [44] and emerging treatment for prevention [45] . Before widely implementing such strategies, mathematical modeling and empirical data are urgently needed to investigate their acceptability, adherence, and the possible consequences for the emergence and spread of drug resistance.
In conclusion, regular viral load monitoring aimed at early failure detection may limit the accumulation of HIV-1 drug resistance. The strengthening of national HIV treatment programs through robust supply chains, routine viral load monitoring, and improved access to alternative drug regimens in subSaharan Africa to prevent drug resistance is an urgent priority. Zidovudine rather than tenofovir may be the preferred second-line NRTI after first-line stavudine failure. The high frequencies of Y181C and accumulated NNRTI mutations limit the effectiveness of second-generation NNRTIs for use in second-line ART. 
